Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT)

June 2, 2026 6:56 AM EDT Send to a Friend
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $95.00 price target on Corcept Therapeutics (NASDAQ: CORT).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login